OBJECTIVE: To learn whether metformin treatment affects oxidative stress as measured by serum concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG). DESIGN: Double-blind, randomized, placebo-controlled trial. SETTING:University outpatient clinic. PATIENT(S): The study cohort consisted of 50 obese women (body mass index [BMI] ≥ 27 kg/m(2)) and60 nonobese patients (BMI <27 kg/m(2)), mean age was 27.7 ± 4.0 SD years. INTERVENTION(S): Randomization to receive metformin or placebo for 3 months. MAIN OUTCOME MEASURE(S): Serum levels of 8-OHdG before and after medical treatment. RESULT(S): The levels of 8-OHdG were equal at baseline in the placebo and metformin groups. Obese women had higher baseline serum concentrations of 8-OHdG. Levels of 8-OHdG were statistically significantly reduced with metformin treatment, especially in obese patients with polycystic ovary syndrome. This study was a secondary subanalysis of a previously conducted prospective multicenter, randomized, placebo-controlled study on the effects of metformin on miscarriage, pregnancy, and miscarriage rates. CONCLUSION(S): Metformin treatment, compared with placebo, statistically significantly decreased 8-OHdG levels in women with polycystic ovary syndrome. CLINICAL TRIAL REGISTRATION NUMBER: NCT00994812.
RCT Entities:
OBJECTIVE: To learn whether metformin treatment affects oxidative stress as measured by serum concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG). DESIGN: Double-blind, randomized, placebo-controlled trial. SETTING: University outpatient clinic. PATIENT(S): The study cohort consisted of 50 obesewomen (body mass index [BMI] ≥ 27 kg/m(2)) and 60 nonobese patients (BMI <27 kg/m(2)), mean age was 27.7 ± 4.0 SD years. INTERVENTION(S): Randomization to receive metformin or placebo for 3 months. MAIN OUTCOME MEASURE(S): Serum levels of 8-OHdG before and after medical treatment. RESULT(S): The levels of 8-OHdG were equal at baseline in the placebo and metformin groups. Obesewomen had higher baseline serum concentrations of 8-OHdG. Levels of 8-OHdG were statistically significantly reduced with metformin treatment, especially in obesepatients with polycystic ovary syndrome. This study was a secondary subanalysis of a previously conducted prospective multicenter, randomized, placebo-controlled study on the effects of metformin on miscarriage, pregnancy, and miscarriage rates. CONCLUSION(S): Metformin treatment, compared with placebo, statistically significantly decreased 8-OHdG levels in women with polycystic ovary syndrome. CLINICAL TRIAL REGISTRATION NUMBER: NCT00994812.
Authors: Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy Journal: PLoS One Date: 2021-07-19 Impact factor: 3.240